[Multiple myeloma. Diagnosis and therapy].
Multiple myeloma is one of the 20 most frequent malignancies in Germany. Initial symptoms are usually non-specific. Assessment of bone marrow and laboratory data as well as imaging techniques are essential for diagnosis and prognostic evaluation. Data from molecular cytogenetics have led to a better understanding of the pathogenesis of multiple myeloma. Cytostatic therapy with alcylating agents and glucocorticoids prolongs the survival. High-dose therapy followed by transplantation of autologous hematopoietic stem cells improves prognosis for patients up to the age of 70. Currently, modifications of allogeneic hematopoietic stem cell transplantation, anti-angiogeneic and immunomodulatory drugs as well as proteasome inhibitors are evaluated in clinical trials. Supportive care has derived benefit from the introduction of new bisphosphonates.
Goldschmidt
H
H
Medizinische Klinik und Poliklinik V, Universität Heidelberg. Hartmut_Goldschmidt@med.uni-heidelberg.de
Cremer
F W
FW
Möhler
T M
TM
Ho
A D
AD
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
D000970:Antineoplastic Agents; D004164:Diphosphonates
Multiples Myelom. Diagnostik und Therapie.